^
    Back
    Association details:
    Biomarker:High IFNG gene signature
    Cancer:Melanoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2021
    Title:

    Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.

    Published date:
    05/19/2021
    Excerpt:
    In pts treated with A+V+C and n-LDH, h-IFN-g signature was associated with longer PFS and higher rates of objective response (OR) and complete response…
    DOI:
    10.1200/JCO.2021.39.15_suppl.9523
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    SITC 2020
    Title:

    307 Atezolizumab plus vemurafenib and cobimetinib provides favorable survival outcomes in patients with high tumor mutation burden and proinflammatory gene signature in the phase 3 IMspire150 study

    Published date:
    11/09/2020
    Excerpt:
    514 patients were randomized 1:1 to A+V+C (n=256) or P+V+C (n=258)….The PFS and DOR benefits were more evident in patients with high IFN-gamma or TMB >10 mutations/Mb.
    DOI:
    http://dx.doi.org/10.1136/jitc-2020-SITC2020.0307